Compare TGTX & DBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGTX | DBX |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.2B |
| IPO Year | 2008 | 2018 |
| Metric | TGTX | DBX |
|---|---|---|
| Price | $36.57 | $28.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $49.80 | $28.14 |
| AVG Volume (30 Days) | 2.0M | ★ 4.1M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1746.67 | 32.86 |
| EPS | 0.12 | ★ 0.48 |
| Revenue | ★ $2,785,000.00 | N/A |
| Revenue This Year | $49.08 | $0.20 |
| Revenue Next Year | $26.69 | N/A |
| P/E Ratio | $305.33 | ★ $58.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.37 | $21.70 |
| 52 Week High | $44.65 | $32.40 |
| Indicator | TGTX | DBX |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 60.78 |
| Support Level | $33.05 | $28.09 |
| Resistance Level | $37.05 | $29.54 |
| Average True Range (ATR) | 1.23 | 0.96 |
| MACD | -0.62 | 0.06 |
| Stochastic Oscillator | 1.83 | 80.75 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.